Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

(2019) Daniel Shae et al.   Nature Nanotechnology

Trojan horses for immunotherapy

(2019) Jeffrey A. Hubbell et al.   Nature Nanotechnology

Autophagic cell death restricts chromosomal instability during replicative crisis

(2019) Joe Nassour et al.   NATURE

Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells

(2018) Jeonghyun Ahn et al.   CANCER CELL

Myeloid cell heterogeneity in cancer: not a single cell alike

(2018) Mate Kiss et al.   CELLULAR IMMUNOLOGY

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-riskMYCN-not-amplified Human Neuroblastoma

(2018) Jun S. Wei et al.   CLINICAL CANCER RESEARCH

TMEM173 variants and potential importance to human biology and disease

(2018) Seema Patel et al.   GENES AND IMMUNITY

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Can innate immune system targets turn up the heat on 'cold' tumours?

(2018) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma

(2018) Elizabeth E. Sweeney et al.   Small

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites

(2018) Zachary S. Morris et al.   Cancer Immunology Research

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

(2018) Irina V. Kholodenko et al.   Journal of Immunology Research

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2018) Kelsey E. Sivick et al.   Cell Reports

CAR T Cell Therapy for Neuroblastoma

(2018) Rebecca M. Richards et al.   Frontiers in Immunology

An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS/STING Pathway in Pan-Cancer

(2018) Xiang An et al.   Molecular Therapy-Nucleic Acids

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death

(2017) Bridget Larkin et al.   JOURNAL OF IMMUNOLOGY

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

(2017) Atif A. Ahmed et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

(2017) Lars Wagner et al.   OncoTargets and Therapy

Signalling strength determines proapoptotic functions of STING

(2017) Muhammet F. Gulen et al.   Nature Communications

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

(2017) Casey R. Ager et al.   Cancer Immunology Research

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

(2017) Jeremy B. Foote et al.   Cancer Immunology Research

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression

(2017) Julian P. Layer et al.   OncoImmunology

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers

(2016) Takahiro Aoki et al.   PEDIATRIC BLOOD & CANCER

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia

(2016) Emily Curran et al.   Cell Reports

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity

(2015) F. Mussai et al.   CANCER RESEARCH

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

(2015) M. S. Merchant et al.   CLINICAL CANCER RESEARCH

Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants

(2015) Melissa C. Hanson et al.   JOURNAL OF CLINICAL INVESTIGATION

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma

(2015) Marco Mina et al.   OncoImmunology

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance

(2015) Alessandra Dondero et al.   OncoImmunology

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival

(2013) Richard K. Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Turning Tumors into Vaccines: Co-opting the Innate Immune System

(2013) Jasper G. van den Boorn et al.   IMMUNITY

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma

(2013) Michiel Kroesen et al.   INTERNATIONAL JOURNAL OF CANCER

The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes

(2013) Lena-Maria Carlson et al.   OncoImmunology

Immunosuppressive Microenvironment in Neuroblastoma

(2013) Vito Pistoia et al.   Frontiers in Oncology

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

(2012) K. A. Cole et al.   CLINICAL CANCER RESEARCH

Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma

(2012) Shahab Asgharzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

(2010) Ilia N. Buhtoiarov et al.   IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma

(2009) Suzanne A. Miles et al.   ADVANCED DRUG DELIVERY REVIEWS

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugsin vitroandin vivo

(2008) Ebba Palmberg et al.   INTERNATIONAL JOURNAL OF CANCER